Asthma and COPD Drugs Market Size, Share & Analysis Report, 2023-2032
The global asthma and COPD drugs market size was exhibited at USD 37.96 billion in 2022 and is projected to hit around USD 40.05 billion by 2032, growing at a CAGR of 5.5% during the forecast period 2023 to 2032.
Key Pointers:
Asthma and COPD Drugs Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 40.05 Billion |
| Market Size by 2032 | USD 64.84 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 5.5% |
| Base year | 2022 |
| Forecast period | 2023 to 2032 |
| Segments covered | Diseases, Medication Class, Distribution Channel |
| Regional scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key companies profiled | Pfizer Inc., Teva Pharmaceutical Industries Ltd, Merck & Co. Inc, Grifols S.A., Novartis AG, Cipla Inc., Abbott, Astellas Pharma, Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals |
Asthma is a non-communicable, chronic inflammatory lung disorder of the airways. Airways hyper-responsiveness leads to recurrent episodes of wheezing, breathlessness, chest tightness, and cough. Asthma is largely reversible as compared to other obstructive lung diseases. Allergy is the strongest risk factor for asthma. Moreover, asthma can be triggered by exposure of irritants, exercise, β blockers, cold air, animals, and dust. The chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. COPD includes emphysema; a complex lung disease characterized by damage to alveoli and chronic bronchitis; a chronic inflammation to lower respiratory track. Tobacco smoking is the major cause for COPD. In addition, passive smoking, occupational exposure, and ambient air pollution are risk factors for COPD.
The asthma and COPD can be diagnosed with physical examination and several tests such as X-ray, sputum eosinophils, and nitric oxide test. Asthma and COPD can be treated with inhaled corticosteroids, leukotriene modifiers, and theophylline. However, acute respiratory attack can be controlled with the short-acting beta agonists and anticholinergic drugs.
The growth of the global Asthma and COPD Drugs Market is majorly driven by the increase in prevalence of asthma and COPD. For instance, according to world health organisation (WHO), asthma affected an estimated 262 million people and caused 46,1000 deaths in 2019. Furthermore, the rise in number of COPD patients contributes to the growth of market. For instance, according to American Lung Organization, 99 million adults had chronic bronchitis and 2 million adults had emphysema in U.S. in 2018.
Moreover, advancement in respiratory diseases therapy and new product launches in the global Asthma and Chronic Obstructive Pulmonary Disease Drugs Market are anticipated to contribute toward the growth of the market. For instance, in December 2020, AstraZenca, a leading manufacturer of pharmaceuticals, received EU Approval for ‘Trixeo Aerosphere’ for maintenance treatment of COPD. However, high cost of associated asthma treatment restricts the market growth during the forecast period.
Some of the prominent players in the Asthma and COPD Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Asthma and COPD Drugs market.
By Diseases
By Medication Class
By Distribution Channel
By Region
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers